Showing 3221-3230 of 5910 results for "".
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho
- Adverum’s Ixo-Vec for Wet AMD Evaluated in 3-Year Data from OPTIC Extension Studyhttps://modernod.com/news/adverums-ixo-vec-for-wet-amd-evaluated-in-3-year-data-from-optic-extension-study/2481951/Adverum Biotechnologies announced updated data from the OPTIC extension study of patients with wet age-related macular degeneration (AMD) and a summary of previously announced aflibercept protein levels from the LUNA study were presented during the Retina Subspecialty Day at AAO 2023 in
- Pantheon Vision Raises $2.5 Million in Seed Funding to Launch Development of Bioengineered Corneal Implanthttps://modernod.com/news/pantheon-vision-raises-25-million-in-seed-funding-to-launch-development-of-bioengineered-corneal-implant/2481936/Pantheon Vision has announced $2.5 million in seed financing from Baltimore-based KeraLink International (KLI), a non-profit organization singularly focused on eradicating corneal blindness with an emphasis on low- and middle-income countries. The funding will be us
- FDA Approves OnPoint Vision’s IDE Application to Begin Phase 1 of IOPCL Magnifierhttps://modernod.com/news/fda-approves-onpoint-visions-ide-application-to-begin-phase-1-of-iopcl-magnifier/2481925/OnPoint Vision announced the FDA approval of their investigational device exemption (IDE) application to begin phase 1 of their pivotal clinical trial of the AccuraSee Intraocular Pseudophakic Capsular Lens (IOPCL) Magnifier (MAG) for secondary implantation in the capsular bag with
- Opthea Announces Changes to Executive Leadershiphttps://modernod.com/news/opthea-appoints-us-based-leadership-with-fred-guerard-as-ceo-and-peter-lang-as-cfo/2481918/Opthea announced that the company’s Chief Executive Officer, Megan Baldwin, PhD, will transition to Founder and Chief Innovation Officer, effective today. The company says the move is reflective of the company’s strategy to advance its US and global presence and commercialization
- Study Shows Efficient AAV Delivery of Large Genes Using ViGeneron's REVeRT Technologyhttps://modernod.com/news/study-shows-efficient-aav-delivery-of-large-genes-using-vigenerons-revert-technology-1/2481913/ViGeneron announced a peer-reviewed publication in
- BioTissue Presents New Data for Cryopreserved Amniotic Membrane Therapyhttps://modernod.com/news/biotissue-presents-new-data-for-cryopreserved-amniotic-membrane-therapy/2481880/Findings of a new multicenter, retrospective study conducted on patients with moderate to severe dry eye disease (DED) treated with BioTissue’s self-retained Prokera Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time, according to
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of